Screener
Mesa Laboratories MLAB Biopharmaceutical Development — Cost Of Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026808
| Three months ended June 30, 2026 | Sterilization and Disinfection Control | Biopharmaceutical Development | Calibration Solutions | Clinical Genomics | Total |
|---|---|---|---|---|---|
| Depreciation in cost of revenue | 437 | 78 | 111 | 119 | 745 |
| Amortization in cost of revenue | 121 | 379 | - | 191 | 691 |
| Other cost of revenue (b) | 6,788 | 4,020 | 5,143 | 3,739 | 19,690 |
| Total segment cost of revenue | 7,346 | 4,477 | 5,254 | 4,049 | 21,126 |
| Gross Profit (c) | $17,159 | $7,582 | $8,031 | $6,240 | $39,012 |
| Reconciling items: | |||||
| Operating expense | $31,981 | ||||
| Operating income | 7,031 |
Document
FAQ
- What is Mesa Laboratories's biopharmaceutical development — cost of revenue?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — cost of revenue of $4.48M in Q2 2026.
- How has Mesa Laboratories's biopharmaceutical development — cost of revenue changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — cost of revenue decreased by 13.6% year-over-year, from $5.18M to $4.48M.
- What is the long-term trend for Mesa Laboratories's biopharmaceutical development — cost of revenue?
- Over 2 years (2024 to 2026), Mesa Laboratories's biopharmaceutical development — cost of revenue has grown at a 14.5% compound annual growth rate (CAGR), from $15.31M to $20.07M.
- What does biopharmaceutical development — cost of revenue mean?
- Represents the total direct costs incurred to produce the goods and services sold by the Biopharmaceutical Development segment. This includes materials, labor, and overhead directly associated with the segment's revenue-generating activities. It is a fundamental metric for evaluating the direct operational efficiency and production cost control of the business unit.
Ask your AI about Mesa Laboratories's biopharmaceutical development — cost of revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude